12th Jan 2015 07:40
LONDON (Alliance News) - Hikma Pharmaceuticals PLC said Monday it will now be preparing to launch its colchicine 0.6 milligram capsules, after Takeda Pharmaceuticals USA Inc failed in its bid to block the distribution of the capsules.
The US District Court for Delaware had denied Takeda's motion for a preliminary injunction in relation to the distribution of Hikma's colchicine capsules, and Himka said Monday that Takeda was unsuccessful in appealing this decision.
Hikma said it will market the colchicine capsules under the brand name Mitigare, and also will prepare to launch an authorised generic of Mitigare to increase "patient access" to the product.
"I am very pleased to be launching our colchicine products, demonstrating our success in developing a more differentiated product portfolio for the US market," said Chairman and Chief Executive Said Darwazah in a statement.
Hikma's colchicine capsules were approved by the US Food and Drug Administration in September last year. The product is used to treat prophylaxis in gout flares.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Hikma Pharmaceuticals